MiNK Therapeutics, Inc.
INKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001840229
No open-market purchases or sales by MiNK Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.39M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding MiNK Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 45 | 2 | 36 | −7 |
| Shares | 1.48M | 2.06K | 723.5K | −751.9K (−51.0%) |
| Value | $3.10M | $4.33K | $800.0K | −$2.29M (−74.1%) |
2 institutions that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (1)
Institutions that held MiNK Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Qube Research & Technologies Ltd | 1,941 | $2.27K | 0.00% |
Sold out (8)
Institutions that held MiNK Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Deep Track Capital, LP | 324,867 | $682.2K |
| Citadel Advisors LLC | 51,048 | $107.2K |
| Virtu Financial LLC | 14,232 | $30.0K |
| D. E. Shaw & Co., Inc. | 11,544 | $24.2K |
| New York State Common Retirement Fund | 31 | $65 |
| Legal & General Group Plc | 8 | $16 |
| Impact Partnership Wealth, LLC | 6 | $13 |
| Front Row Advisors LLC | 1 | $0 |
Not filed for Q3 2023 yet (2)
Institutions that held MiNK Therapeutics, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| First Command Bank | 1,031 | $2.17K |
| First Command Financial Services, Inc. | 1,031 | $2.17K |